Treatment of Venous Thromboembolism in Real-Life Patients

Bristol-Myers Squibb89,383 enrolled

Overview

In a population of patients with venous thromboembolism and treated with oral anticoagulants (OAC) in routine clinical practice in Denmark this study will describe patients treated with each OAC

Study Type

OBSERVATIONAL

Enrollment

89,383

Conditions

Venous Thromboembolism

Interventions

Non-InterventionalOTHER

Non-Interventional

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. All patients ≥ 18 years diagnosed with incident VTE at Danish public hospitals from 2006 through 2015 2. First-time (index) VTE will be defined as an in- or out-patient diagnosis of DVT or PE among patients redeeming a prescription for anticoagulant drugs within 30 days after index date Exclusion Criteria: 1\. In the analyses on type and duration of anticoagulant use, Patients with cancer will be excluded as they typically receive low molecular heparin directly from the hospital and their use of anticoagulants can therefore not be captured by redeemed prescriptions at pharmacies.

Outcomes

Primary Outcomes

Hospitalization rate in VKA patients for VTE

Hospitalization rate for first-time Venous thromboembolism (VTE) in Vitamin K antagonist (VKA) patients